Bannerbild German Brest Group

GBG Research at SABCS

29.11.2018

Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

Clinical trials

Breast Cancer in Pregnancy (BCP) registry (GBG 29), NCT 00196833: oncological management and outcome in young non-pregnant patients with breast cancer

#P1-17-07 Cancer management and outcome of very young non-pregnant patients with breast cancer diagnosed at 40 years or younger–GBG 29

  • Session: Poster session 1, Wednesday, December 5, 5:00 pm – 7:00 pm (poster)
  • First author: S. Seiler; GBG, Neu-Isenburg, Germany


BMBC registry (GBG 79): validation of a breast-GPA score to estimate the prognosis of breast cancer patients with brain metastases
#P4-08-26 Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)

  • Session: Poster Session 4–Friday, December 7, 7:00 am – 9:00 am (poster)
  • First author: ID Witzel, University Medical Center, Hamburg, Germany


KATHERINE (GBG 77), NCT01772472: first results
#GS1-10 Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE

  • Session: General Session 1–Hall 3, Wednesday, December 5, 11:00 am (oral presentation)
  • First author: CE Geyer Jr., Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA


GeparDouze (GBG 96, NSABP B-59), NCT03281954: trial in progress
#OT3-05-01 A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with Triple Negative Breast Cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

  • Session: Poster Session OT3–Friday, December 7, 5:00 pm – 7:00 pm (poster)
  • First author: CE Geyer Jr., Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA


ALEXANDRA/IMpassion030 (GBG 98, BIG 16-05, AFT-27), NCT03498716: trial in progress
#OT3-05-02 ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

  • Session: Poster Session OT3–Friday, December 7, 5:00 pm – 7:00 pm (poster)
  • First author: M Ignatiadis, Institut Jules Bordet, Brussels, Belgium



PATINA (GBG 94, AFT-38), NCT02947685: trial in progress
#OT3-02-07 PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

  • Session: Poster Session OT3–Friday, December 7, 5:00 pm – 7:00 pm (poster)
  • First author: O Metzger, Dana Farber Cancer Institute, Boston, USA

Translational research

GeparNuevo (GBG 89): results of biomarker analyses
#PD2-07 mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)-Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

  • Session: Spotlight Session 5–Thursday, December 6, 5:00 pm – 7:00 pm (poster discussion)
  • First author: S. Loibl; GBG, Neu-Isenburg, Germany


#PD5-05 Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial

  • Session: Spotlight Session 5–Thursday, December 6, 5:00 pm – 7:00 pm (poster discussion)
  • First author: B. Sinn; Institut für Pathologie, Charité-Universitätsmedizin Berlin


#P4-08-26 Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial

  • Session: Poster Session 4–Friday, December 7, 7:00 am – 9:00 am (poster)
  • First author: C Massa, Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany


Pooled data from the neoadjuvant trials GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto: retrospective analysis to identify factors in predicting relapse despite a pCR in early breast cancer patients
#P2-08-01 Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database

  • Session: Poster Session 2–Thursday, December 6, 7:00 am – 9:00 am (poster)
  • First author: J. Huober; Universitätsfrauenklinik Ulm, Brustzentrum, Germany


Pooled data from GeparQuinto, GeparSixto and GeparSepto trials: retrospective analysis of hormone receptor phenotype in patients with breast cancer
#P2-08-10 Similarities between low hormone receptor positive and hormone receptor negative breast cancer: An analysis of 4366 patients from multicenter clinical trials

  • Session: Poster Session 2–Thursday, December 6, 7:00 am – 9:00 am (poster)
  • First author: SL Villegas, Institute of Pathology, Charité Universitätsmedizin Berlin


LEA (GBG 51, GEICAM/2006-11), NCT00545077: pooled data from LEA and C40503 trials
#P2-07-05 A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy

  • Session: Poster Session 2–Thursday, December 6, 7:00 am – 9:00 am (poster)
  • First author: M-YC Polley, Mayo Clinic, Rochester, MN, USA



News

  • 01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.

    Mehr ...
  • 04.02.2019 ESMO Breast Cancer 2019

    ESMO Breast Cancer 2019

    ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.

    Mehr ...
  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

    Mehr ...
  • 18.01.2019 Prof. Loibl among highly cited researchers 2018

    Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.

    Mehr ...
  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd